Capacity Planning at Genentech Student Worksheet

Adapted from Exhibit 12 Expected Penetration

Cancer

Patients 2005 2010 2015

Colorectal Cancer Treatment

front-line 40,000 55% 60% 65%
second-line 20,000 35% 35% 35%
other 120,000 5% 10% 15%

Grams per dose

Doses per year
Total grams per patient treated

Total grams for colorectal patients

Total kg for colorectal patients

Trial Probability of
Other Cancer indications Stage Trial Success
Lung
front-line 100% 75,000 5% 30% 30%
other 100% 35,000 2% 15% 15%
Breast
front-line 100% 140,000 30% 30%
other 100% 80,000 15% 15%
Kidney
front-line 100% 18,000 30% 30%
other 100% 18,000 15% 15%
Pancreatic
front-line 100% 16,000 30% 30%
other 100% 16,000 15% 15%
Other
front-line 100% 25,000 15% 30%
other 100% 25,000 8% 15%

Total patients

Grams per dose

Doses per year
total grams per patient treated

Total grams to treat other cancer indications

Total kg to treat other cancer indications

Total kg required for colorectal and other

cancer indications
heet

Estimated Number of Patients Using Avastin

2005 2010 2015

22,000 24,000 26,000

7,000 7,000 7,000
6,000 12,000 18,000
35,000 43,000 51,000

0.375 0.375 0.375

20 20 20
7.5 7.5 7.5

262,500 322,500 382,500

263 323 383

3,750 22,500 22,500

700 5,250 5,250

0 42,000 42,000
0 12,000 12,000

0 5,400 5,400
0 2,700 2,700

0 4,800 4,800
0 2,400 2,400

0 3,750 7,500
0 2,000 3,750

4,450 102,800 108,300

0.75 0.75 0.75

 12 12 12
9 9 9

40,050 925,200 974,700

40 925 975

303 1248 1357

 Capacity Planning at Genentech

Kg/Batch
Recovered
Capacity/Tank Kg/Batch Less Bad
Tanks Liters Batches/yr Kg/batch Recovered Batches
SSF 8 12000 15 9.0 5.9 4.7
CCP1 12 12000 15 9.0 5.9 4.7
CCP2 8 25000 15 18.8 12.2 9.8
CCP3
Porrino 4 10000 15 7.5 4.9 3.9
Rituxan Outsource 2 10000 15 7.5 4.9 3.9
Herceptin Outsource 2 10000 15 7.5 4.9 3.9

st dev as % of mean
85%-ile demand 1

2005 2006 2007 2008 2009 2010 2011

SSF 561.6 561.6 561.6 561.6 561.6 561.6 561.6
CCP1 842.4 842.4 842.4 842.4 842.4 842.4 842.4
CCP2 1170 1170 1170
CCP3 0 0 0 0 0 0 0
Porrino 234.0 234 234 234 234 234 234
Rituxan Outsource 117.0 117.0 117.0 117.0 117.0 117.0 117.0
Herceptin Outsource 117.0 117.0 117.0 117.0 117.0 117.0 117.0

Genentech Capacity 1638 1638 1638 1638 2808 2808 2808

Outsource Capacity 117 234 234 234 234 0 0
Total Capacity 1755 1872 1872 1872 3042 2808 2808

Avastin Demand 303 492 681 870 1059 1248 1270

Other Drug Demand 1000 1050 1100 1150 1200 1250 1313
Omnitarg 0 50 100 150 200 250 300
Total Expected Demand 1303 1592 1881 2170 2459 2748 2882

85%-ile demand 2605 3183 3761 4339 4917 5495 5764

GAP 733 1311 1889 2467 1875 2687 2956

 96000
144000
200000

40000
20000
20000

2012 2013 2014 2015

561.6 561.6 561.6 561.6
842.4 842.4 842.4 842.4
1170 1170 1170 1170
0 0 0 0
234 234 234 234
117.0 117.0 117.0 117.0
117.0 117.0 117.0 117.0

2808 2808 2808 2808

0 0 0 0
2808 2808 2808 2808

1292 1313 1335 1357

1375 1438 1500 1563
350 400 450 500
3017 3151 3285 3420

6033 6302 6571 6839

3225 3494 3763 4031

 Capacity Planning at Genentech

Kg/Batch
Recovered
Capacity/Tank Kg/Batch Less Bad
Tanks Liters Batches/yr Kg/batch Recovered Batches
SSF 8 12000 15 9.0 5.9 4.7
CCP1 12 12000 15 9.0 5.9 4.7
CCP2 8 25000 15 18.8 12.2 9.8
CCP3 12 25000 15 18.8 12.2 9.8
Porrino 4 10000 15 7.5 4.9 3.9
Rituxan Outsource 2 10000 15 7.5 4.9 3.9
Herceptin Outsource 2 10000 15 7.5 4.9 3.9

st dev as % of mean
85%-ile demand 1

2005 2006 2007 2008 2009 2010 2011

SSF 561.6 561.6 561.6 561.6 561.6 561.6 561.6
CCP1 842.4 842.4 842.4 842.4 842.4 842.4 842.4
CCP2 1170 1170 1170
CCP3
Porrino 234.0 234 234 234 234 234 234
Rituxan Outsource 117.0 117.0 117.0 117.0 117.0 117.0 117.0
Herceptin Outsource 117.0 117.0 117.0 117.0 117.0 117.0 117.0

Genentech Capacity 1638 1638 1638 1638 2808 2808 2808

Outsource Capacity 234 234 234 234 234 234 234
Total Capacity 1872 1872 1872 1872 3042 3042 3042

Avastin Demand 303 492 681 870 1059 1248 1270

Other Drug Demand 1000 1050 1100 1150 1200 1250 1313
Omnitarg 0 50 100 150 200 250 300
Total Expected Demand 1303 1592 1881 2170 2459 2748 2882

85%-ile demand 2605 3183 3761 4339 4917 5495 5764

GAP 733 1311 1889 2467 1875 2453 2722

 96000
144000
200000
300000
40000
20000
20000

2012 2013 2014 2015

561.6 561.6 561.6 561.6
842.4 842.4 842.4 842.4
1170 1170 1170 1170
1755
234 234 234 234
117.0 117.0 117.0 117.0
117.0 117.0 117.0 117.0

2808 2808 2808 4563

234 234 234 234
3042 3042 3042 4797

1292 1313 1335 1357

1375 1438 1500 1563
350 400 450 500
3017 3151 3285 3420

6033 6302 6571 6839

2991 3260 3529 2042

8000

7000

6000

5000

4000

3000

2000

1000

0
1 2 3 4 5 6 7
Row 33 Movi ng average (Row 33) Tota
 5 6 7 8 9 10 11
rage (Row 33) Tota l Expected Demand Tota l Ca paci ty